Agenus to Participate in February Investor Conferences

Rhea-AI Summary

Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen, Chairman and CEO, along with Dr. Steven O’Day, Chief Medical Officer, will present at two upcoming investor conferences. The Guggenheim 5th Annual Oncology Day will feature a fireside chat on February 9, 2023, at 9:35 AM ET, while the SVB Securities Global Biopharma Conference will host a virtual fireside chat on February 16, 2023, at 10:00 AM ET. Interested parties can access live webcasts through the company’s website. Agenus focuses on cancer immunotherapy, leveraging various therapeutic approaches and resources.

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, will participate in the following upcoming investor conferences:

• Guggenheim 5^th Annual Oncology Day – Fireside chat presentation will be held in-person on Thursday, February 9th, 2023 at 9:35 AM ET
  
• SVB Securities Global Biopharma Conference – Fireside chat presentation will be held virtually on Thursday, February 16th, 2023 at 10:00 AM ET
  

A live webcast of the presentations from Guggenheim and SVB Securities conferences can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations. A replay will be posted following the event.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

FAQ

When will Agenus participate in the Guggenheim 5th Annual Oncology Day?

Agenus will participate in the Guggenheim 5th Annual Oncology Day on February 9, 2023, at 9:35 AM ET.

What is the date and time for the SVB Securities Global Biopharma Conference presentation by Agenus?

Agenus will present at the SVB Securities Global Biopharma Conference on February 16, 2023, at 10:00 AM ET.

How can I watch the Agenus conference presentations online?

You can access the live webcasts of the Agenus conference presentations on their website.

What is the focus of Agenus as an immuno-oncology company?

Agenus focuses on developing therapies that engage the immune system to fight cancer and infections.

Who will be presenting at the upcoming investor conferences for Agenus?

Dr. Garo Armen and Dr. Steven O’Day will be presenting at the upcoming investor conferences for Agenus.